EUCTR2017-000367-33-FR进行中（未招募）1 期
Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients must have metastatic or advanced solid tumors.
- •- Women with histologically or cytologically confirmed triple negative breast carcinoma.
- •- Participants with histologically confirmed pancreatic adenocarcinoma.
- •- Participants must have histologic or cytologic confirmation of Non Small Cell Lung Cancer (NSCLC).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 66
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 94
排除标准
- •-Active brain metastases or leptomeningeal metastases.
- •- Any serious or uncontrolled medical disorder.
- •- Prior malignancy active within the previous 3 years.
研究者
相似试验
进行中（未招募）
1 期
The purpose of this study is to determine whether an investigational combination immuno-therapy of nivolumab and daratumumab is safe and effective in thetreatment of advanced or metastatic solid tumors.Advanced or metastatic solid tumorsMedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000367-33-ESBristol-Myers Squibb International Corporation105
进行中（未招募）
1 期
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have SpreadEUCTR2017-000367-33-DEBristol-Myers Squibb International Corporation160
进行中（未招募）
1 期
The purpose of this study is to determine whether an investigationalcombination immuno-therapy of nivolumab and daratumumab is safe andeffective in the treatment of advanced or metastatic solid tumors.Advanced or metastatic solid tumorsMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000367-33-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO105
进行中（未招募）
不适用
A Phase IIA Study to Evaluate the Safety and Preliminary Efficacy of Resten-MP when used in Conjunction with a Bare Metal Stent in de novo Native Coronary Artery Lesions - APPRAISAEUCTR2005-000713-35-DEAVI BioPharma Inc.50
进行中（未招募）
1 期
A Safety and Efficacy Study of Nivolumab in Combination with Brentuximab Vedotin to Treat Non-Hodgkin LymphomasEUCTR2015-003286-28-GBBristol-Myers Squibb International Corporation170